Skip to content
Menu

4D Molecular Therapeutics Q3 EPS $(1.08) Misses $(1.05) Estimate, Sales $4.100M Beat $2.700M Estimate

Benzinga Newsdesk 1 week ago

NewsEarningsEarnings BeatsEarnings Misses

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(1.05) by 2.86 percent. This is a 6.93 percent decrease over losses of $(1.01) per

4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(1.05) by 2.86 percent. This is a 6.93 percent decrease over losses of $(1.01) per share from the same period last year. The company reported quarterly sales of $4.100 million which beat the analyst consensus estimate of $2.700 million by 51.85 percent. This is a 4.46K percent increase over sales of $90.000 thousand the same period last year.

Read at benzinga.com